康臣药业(01681.HK)：上半年肾科产品稳中有增，探索电商和新零售等机会
格隆汇 8 月 24日丨康臣药业(01681.HK)公布中期业绩，截至2020年6月30日止6个月，公司收入为人民币7.66亿元%；公司权益股东应占溢利为人民币2.09亿元。每股基本盈利为人民币0.2527元，拟派中期息每股0.08港元。
集团于截至2020年6月30日止六个月的收入为人民币7.66亿元。按产品系列分类，肾科系列产品销售较去年录得增长约4.9%，其中尿毒清颗粒仍然是集团的皇牌产品，维持在肾病口服现代中成药市场的领先地位；医用成像对比剂销售虽然较去年减少约24.9%，仍然稳占国内磁共振成像对比剂市场的前列；骨伤系列产品销售下降约45.6%；皮肤系列产品销售下降约79.2%；妇幼系列产品销售减少约15.6%；及其他药物销售减少约59.7%。整体销售收入的减少主要是由于期内受新冠肺炎疫情影响，医用成像对比剂、妇幼系列产品及玉林制药分部的销售收入下跌所致。
于2020年上半年，集团的毛利为人民币5.72亿元。于2020年上半年，集团的平均毛利率为74.6%，与2019年同期的73.0%相比，增加1.6%，主要是由于期内产品销售结构变化所致。
公告称，于2020年上半年，集团的经营活动净现金流入为人民币3.24亿元，相比2019年同期的人民币1.40亿元增加约131.5%，主要是由于期内加大贸易应收账款催收力度所致。于2020年6月30日，集团的现金及银行结余为人民币15.21亿元，相比2019年12月31日的余额人民币13.83亿元增加约10.0%。
在这个复杂多变、外部环境日益恶化的时代，管理层首要的任务是掌好舵，把握好康臣的发展方向，让康臣旗舰行驶得更稳。通过落实"精耕、精炼、精神"三精的要求，以"逆周期扩张思维"，把握住彼退我进中的错位机会，包括探索电商和新零售等机会，在"六保、一稳"上下功夫，达到凝心聚力，提速前进的核心目的：
1)确保能把握随时可能出现的业务分拆机会；2)确保影像诊断业务快速发展；3)确保肾科药物维持在肾病口服现代中成药的领先；4)确保玉林制药变革方案的成功落实；5)确保研发创新力量的不断壮大，务求以肾病药物为主的"1+6"方面新产品源源不断注入；6)确保集团稳定而充足的现金流，而一稳就是实现集团稳定持续的增长。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
